Mrs K, aged 64 years, was admitted to the hospital for markedly elevated blood pressure with subsequent development of nonoliguric renal insufficiency. Upon admission, it was noted that a rash had been present for 2 to 3 weeks. The rash, described as erythematous plaques not involving the nose, was found bilaterally over the cheeks, forearms, scalp, chest, and back. The patient denied other symptoms associated with lupus erythematosus, including polyarthralgia, pleurisy, sun sensitivity, Raynaud's phenomenon, and extremity paresthesias. There was no evidence of connective tissue disease in her past medical history. Her psychiatric history was remarkable for depression with psychosis, for which she received ziprasidone 20 mg daily for approximately 5.5 months.
Mrs K, aged 64 years, was admitted to the hospital for markedly elevated blood pressure with subsequent development of nonoliguric renal insufficiency. Upon admission, it was noted that a rash had been present for 2 to 3 weeks. The rash, described as erythematous plaques not involving the nose, was found bilaterally over the cheeks, forearms, scalp, chest, and back. The patient denied other symptoms associated with lupus erythematosus, including polyarthralgia, pleurisy, sun sensitivity, Raynaud's phenomenon, and extremity paresthesias. There was no evidence of connective tissue disease in her past medical history. Her psychiatric history was remarkable for depression with psychosis, for which she received ziprasidone 20 mg daily for approximately 5.5 months.
Rheumatology and dermatology consults were obtained. Both consultants felt that she was likely suffering a reaction to the ziprasidone, rather than a connective tissue disease. Serum autoantibodies, rheumatoid factor, erythrocyte sedimentation rate (sed rate), and punch biopsy were obtained to evaluate the rash. Results of serum tests showed a slightly elevated sed rate at 45 mm/Hr and a positive result for SS-A/Ro autoantibodies at 162.7. Other serum autoantibodies used as markers for druginduced lupus were negative. Results of the punch biopsy were consistent with a drug-induced rash caused by type 3 or 4 hypersensitivity reaction. A literature search on the other medications currently taken by the patient did not reveal an association with drug-induced lupus. Administration of ziprasidone was discontinued, and Mrs K was switched to risperidone at 1 mg daily. She was seen by the consulting dermatologist 4 days after the initial consultation. The dermatologist noted that her rash had improved over the intervening 4 days. Discontinuation of the ziprasidone in conjunction with rapid improvement of signs and symptoms is consistent with the diagnosis of DILE. To our knowledge, this is the first reported case of DILE owing to ziprasidone; thus, it is likely an uncommon phenomenon. Perhaps as our experience with ziprasidone expands, the relevance of DILE as a side effect will be further elucidated.
Lorazepam-Induced Prolongation of the QT Interval in a Patient With Schizoaffective Disorder and Complete AV Block
Dear Editor:A wide range of noncardiovascular therapeutic agents have been shown to prolong the QT interval. The large scope of this problem has created an issue for drug developers and health authorities and is of critical importance for attending physicians (1) . The noncardiac agents associated with QT prolongation belong to many different pharmacologic classes, including psychotropic drugs, prokinetic medicines, antimalarial medicines, antibiotics belonging to several different chemical classes, antifungal agents, and nonsedating antihistamines (2) . In many cases, psychotropic drugs, particularly tricyclic antidepressants and antipsychotic agents, are correlated with iatrogenic prolongation of the QT interval of the ECG (3). This is associated with dangerous polymorphic ventricular tachyarrhythmia torsades de pointes and sudden death. In addition to ventricular conduction time, the QT interval of the ECG reflects the duration of the ventricular action potential (AP) at the cellular level. Thus, the prolongation of the QT interval may reflect effects on ion channels involved in ventricular AP generation. However, the QT interval also depends on the heart rate, and therefore, the determination of QT prolongation in patients is usually measured using the heart-rate corrected QT interval. Vulnerability to medicationinduced prolongation of the QT interval may also reside in the patient, with respect to the underlying psychiatric diagnosis, any underlying medical illness (especially cardiovascular disease), genetic predisposition to drug-induced QT prolongation (4), and patient age. The interactions between different psychotropic drugs used in combination or used with other medications that have known effects on the cardiovascular system may also lead to QT prolongation and risk of arrhythmia.
QT prolongation during lorazepam therapy has not been documented in the literature. We present a case of lorazepam-induced severe QT prolongation.
Case report
A woman, aged 40 years, with an acute schizomanic episode, a third-degree atrioventricular (AV) block, and cardiovascular disease meeting ICD-10 criteria was admitted to our psychiatric hospital. The ECG showed the complete AV block (heart rate 45 bpm, QT interval 394 ms), and the blood tests revealed abnormal findings (elevated creatine kinase and creatine kinase-MB isoenzyme, normal troponin T, and elevated liver enzymes). The electroencephalogram and the brain CT revealed no abnormal findings. Because of the severe symptoms, psychopharmacotherapy with 12.5 mg quetiapine, 100 mg trimipramine, 40 mg pipamperone, and 5 mg diazepam daily was started. The psychopharmacotherapy had no influence on the QT interval. At day 6, 0.5 mg lorazepam was given 3 times, inducing QT prolongation up to 580 ms. Psychopharmacotherapy was discontinued, and the patient was admitted to the medical department for 1 day. The QT prolongation persisted for 7 days, and according to the international treatment criteria, the insertion of a cardiac pacemaker was mandatory. On day 16, a permanent cardiac pacemaker with dualchamber pacing (that is, DDD mode) was implanted. Afterwards, a sophisticated psychopharmacotherapeutic regimen was established, and the patient responded to the therapy.
In this case, we found a constellation of putative risk factors for the development of QT prolongation. We hypothesize that lorazepam induced the QT prolongation. For a given medication, arrhythmogenic risk must be understood to be partially mechanistically dependent on vulnerability intrinsic to the individual patient with regard to the particular drug. We suggest cautious use of psychotropic drugs in patients with risk factors.
